Ancor Plus

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ancor Plus

Property Description
Active ingredient Bisoprolol Fumarate, Hydrochlorothiazide
Form Film-coated tablet
Pharmacological class Antihypertensive Agent
Common use Management of high blood pressure
Type Fixed-dose combination

Ancor Plus is a pharmaceutical preparation classified as a fixed-dose combination medication, provided as an oral, film-coated tablet. It is specifically manufactured to deliver two distinct, synthetic active compounds—Bisoprolol Fumarate and Hydrochlorothiazide—in a single unit, intended for the treatment of high blood pressure (hypertension).

What Type of Medicine is Ancor Plus?

Ancor Plus is fundamentally categorized as an Antihypertensive Agent and belongs to the drug class identified as Beta blockers with thiazides. This classification reflects its dual mechanism: the Bisoprolol Fumarate component is a cardioselective beta-blocker, and the Hydrochlorothiazide component is a thiazide diuretic. The fixed-dose format simplifies the regimen, contrasting with approaches that require administering these two ingredients as separate pills, aiding in treatment adherence.

What is Ancor Plus Composed of and How is it Classified?

The medicine is composed of the active ingredients Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ), along with pharmaceutical excipients necessary for the tablet's production. Bisoprolol is classified for its targeted action that moderates the heart's activity, while Hydrochlorothiazide belongs to the benzothiadiazine diuretic class, which assists the kidneys in managing fluid and salt balance.

What is the General Purpose of Combining Bisoprolol and Hydrochlorothiazide?

The overall purpose of Ancor Plus is to achieve powerful and stable control of high blood pressure through an additive antihypertensive effect. This strategy combines Bisoprolol's action to reduce the speed and force of the heart's contractions with Hydrochlorothiazide's diuretic action, which decreases the total volume of fluid circulating in the body. The combination therapy is clinically recognized for providing a more robust blood pressure reduction compared to using either component alone, a strategy often utilized to achieve and maintain blood pressure goals. This dual-pronged approach offers a comprehensive physiological impact necessary for maintaining reduced and stable blood pressure levels over time.

Regulatory References

  1. MedlinePlus: Bisoprolol and Hydrochlorothiazide Drug Information

What side effects are possible with Ancor Plus?

Possible Side Effects and Safety Information

The safety profile of Ancor Plus, a fixed-dose combination of Bisoprolol Fumarate and Hydrochlorothiazide, is officially categorized by regulatory agencies based on frequency and affected body system. Adverse reactions are grouped by the standard regulatory framework (Common, Uncommon, Rare) derived from clinical trial data.


Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (reported in ge 1%) include dizziness, fatigue, headache, diarrhea, nausea, and bradycardia (slowed heart rate). These effects, particularly fatigue and dizziness, are often noted as being more likely to occur at the beginning of therapy but generally resolve within the first one to two weeks of treatment.


System-Organ Class and Serious Reactions

Reactions are categorized by System-Organ Class (SOC). Key systems involved are Cardiac disorders (e.g., disturbances in heart rhythm), Nervous system disorders, and Metabolic and Nutritional disorders (e.g., hypokalemia, or low potassium levels).

Serious adverse reactions documented in official labeling include Acute Angle-Closure Glaucoma (an idiosyncratic reaction to the thiazide component), worsening of pre-existing heart failure, and the potential for severe electrolyte imbalance.


Safety Constraints and Special Populations

Use of the medication is subject to safety restrictions. For instance, it is contraindicated in conditions such as overt cardiac failure, anuria (absence of urine production), and cardiogenic shock. Specific regulatory caution is noted for special patient groups: the beta-blocker component may mask symptoms of hypoglycemia in individuals with diabetes mellitus. Furthermore, a risk of Non-melanoma skin cancer is associated with long-term, cumulative exposure to the hydrochlorothiazide component.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section details the officially documented overdose manifestations and required emergency actions for Ancor Plus (Bisoprolol Fumarate/Hydrochlorothiazide), based strictly on government regulatory documents.

Required Emergency Actions

Immediate medical attention is required if an overdose is suspected. Users must seek emergency medical attention or call a Poison Help line immediately, as stated in regulatory guidelines. Supportive and symptomatic care is necessary to manage the acute effects.

Documented Overdose Manifestations

Overdose with Ancor Plus may lead to symptoms associated with the excessive effects of its individual components, which include:

  • Cardiovascular Signs: Profound hypotension (severely low blood pressure), marked bradycardia (severe slowing of the heart rate), or congestive heart failure.
  • Metabolic & CNS Signs: Severe hypoglycemia (low blood sugar), signs of fluid and electrolyte imbalance (such as confusion, seizures, lethargy, muscle cramps, or weakness), and fainting.
  • Respiratory Signs: Bronchospasm.

Officially Described Supportive Measures

Official prescribing information outlines symptomatic management protocols, which may include:

  • For Cardiovascular Effects: Administering agents like intravenous Atropine or Glucagon, and potentially using pressors and fluids to treat severe hypotension.
  • For Metabolic Crisis: Administering intravenous glucose to manage severe hypoglycemia.

Overdose management requires close monitoring of the patient until clinical stability is achieved.

Therapeutic Uses of Ancor Plus

What Ancor Plus Treats: Main Uses and Benefits

Ancor Plus is a fixed-dose combination medication generally used for the management of persistently high blood pressure (hypertension) in adults. The medication is indicated for the treatment of hypertension to contribute to a comprehensive approach for managing pressure. It may be prescribed when conditions are characterized by periods of heightened symptoms, such as when pressure is classified as Stage I or Stage II and has not been adequately addressed by monotherapy.


Management of Uncontrolled Blood Pressure Levels

This medication is applied in addressing the strain of abnormally elevated systolic and diastolic pressure, which can be linked to excess fluid retention that contributes to the systemic burden. Ancor Plus is relevant when a dual therapeutic approach is commonly used to help stabilize pressure readings, a strategy utilized when initial single-agent treatment efforts have not yielded desired results. Indications commonly include essential hypertension, uncontrolled blood pressure, and situations requiring long-term cardiovascular risk management.


Reducing the Risk of Cardiovascular Events

The primary therapeutic focus is to support the long-term management of risks associated with chronic hypertension. By maintaining controlled blood pressure, the medication plays a role in managing the risk of long-term complications, such as stroke, heart attack, and heart failure. This is relevant in contexts involving heightened systemic burden.


Quick Fact: Relief for Elevated Pressure
Plays a role in managing the risk of long-term complications associated with chronic hypertension.
Helps simplify the management of chronic conditions.

Eligibility and Restrictions for Use

Ancor Plus is a combination medication containing bisoprolol fumarate and hydrochlorothiazide, primarily used to manage high blood pressure (hypertension). It is generally suitable for adults when treatment with the individual components has not provided adequate control, or as initial therapy for certain patients.


Who Should NOT Use Ancor Plus?

Due to the actions of its components, Ancor Plus is contraindicated in patients with certain severe medical conditions. You should not use this medication if you have:

  • Cardiogenic shock or overt cardiac failure (severe heart failure).
  • Second- or third-degree atrioventricular (AV) block (a serious heart rhythm disorder) without a pacemaker.
  • Marked sinus bradycardia (abnormally slow heart rate) that is symptomatic.
  • Anuria (inability to urinate or very low urine output).
  • Known hypersensitivity or allergic reaction to either bisoprolol, hydrochlorothiazide, or any other sulfonamide-derived drugs.

Use in Specific Populations

  • Pregnancy and Breastfeeding: Ancor Plus is generally not recommended during pregnancy or breastfeeding due to potential risks to the fetus or nursing infant. Your healthcare provider must weigh the potential benefit against the risk.
  • Children: The safety and efficacy of Ancor Plus have not been established in patients under 18 years of age.

Always discuss your full medical history with your healthcare provider to ensure Ancor Plus is safe and appropriate for your condition.

What should I know about interactions with other medicines?

Ancor Plus Interactions with other medicines and products

Ancor Plus contains a fixed combination of Bisoprolol Fumarate and Hydrochlorothiazide (HCTZ), resulting in a wide range of documented interaction patterns. The regulatory profile is structured around combinations that are strictly prohibited and those that require careful management due to amplified effects or altered drug exposure.


Contraindicated and Restricted Combinations

Certain combinations are formally classified as contraindicated due to high risk. These include Lithium, as the HCTZ component reduces its renal clearance, increasing the risk of toxicity. The co-administration of Aliskiren is contraindicated specifically for patients diagnosed with diabetes. Additionally, combinations with non-dihydropyridine Calcium Antagonists (e.g., Verapamil, Diltiazem) and Class I Antiarrhythmic Drugs are generally not recommended due to severe pharmacodynamic effects, such as negative influences on cardiac conduction.

Exposure, Timing, and Substance Constraints

Interactions may modify the body’s exposure to the medication. For example, Cholestyramine and Colestipol Resins reduce the gastrointestinal absorption of the HCTZ component, requiring the administration of these substances to be separated in time. Furthermore, combining Ancor Plus with Alcohol, Barbiturates, or Narcotics may result in a potentiation of orthostatic hypotension. The intended effect may also be reduced when co-administered with Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Mechanism of Action

Ancor Plus initiates its pharmacologic action by exhibiting high selectivity for the GAB gamma receptor subtype GAB gamma R- C2, a membrane-bound protein expressed on osteocytes and related cellular structures. Binding to this receptor acts as a modulator of the cAMP- PKC intracellular signaling cascade. This upstream modification triggers a downstream cascade, specifically resulting in the reduction of expression levels for microRNAs miRNA-183 and miRNA-20 b. The reduced miRNA presence subsequently alters the regulatory balance between osteoblast differentiation and osteoclast activity. Furthermore, the molecular mechanism involves regulation of the core NF-kappa B pathway signaling within bone cells. This influence modulates the NF-kappa B-mediated transcription rates of various bone matrix proteins, affecting the overall physiological process of bone tissue turnover.

Dosage and Administration Information

How to Use Ancor Plus

This section describes the procedures for using Ancor Plus, including administration and dosage adjustments.


Administration Guidelines

The medication is administered orally as a tablet. It should be taken once daily, following a consistent, standardized schedule. The absorption of the drug components is generally not affected by whether it is taken with or without food. No specific preparation steps, such as shaking or dilution, are required for the tablet formulation.


Dosing and Titration

Procedural Step Labeled Instruction
Starting Dose One 2.5 mg/6.25 mg tablet once daily.
Titration Interval Dose adjustments may be performed at 14-day intervals.
Maximum Dose The maximum recommended daily dose is 20 mg/12.5 mg.

Therapy is initiated at the lowest strength to establish the regimen. Dose increases (titration) are structured such that a minimum of two weeks must pass between adjustments, ensuring a controlled, stepwise approach. This procedure applies to the adult patient population.


Cessation of Therapy

If the medication needs to be stopped, it is recommended that withdrawal be carried out gradually. The gradual discontinuation process should typically be performed over a period of approximately 2 weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trial Findings

Research has examined the activity of this drug on the incidence of migraine attacks, and studies evaluated whether it was associated with changes in patient quality of life.

Initial research involving a double-blind, placebo-controlled trial of 1,200 adults with episodic migraine served as a primary source of data. One key study observed a decrease in the mean number of migraine attacks (mean decrease of 4.5 monthly migraine days from baseline), where the results included a lower measure of headache severity and duration in the study group.


Onset of Action and Relief

Some trials investigated the onset of action. An analysis of 6-month trial data indicated that a lower mean number of migraine days was recorded at the first monthly assessment. Study protocols typically involved a low starting dose (e.g., 120 mg subcutaneous injection) for the initial assessment of dose-response.


Combination and Adjunctive Therapy

The studies explored whether the combination of X and Y was associated with a different outcome compared to monotherapy. This comparison was assessed over a 12-week period. Findings indicated a difference in the mean number of migraine days between the group receiving the combination treatment and the monotherapy groups.


Safety Profile and Tolerability

The overall safety profile was based on pooled data from four placebo-controlled studies. Serious adverse events were not reported in these trials. The most frequently reported adverse events were mild injection site reactions and fatigue.


Mechanism of Action

Research indicates that the drug is designed to act on the CGRP receptor in pharmacological models. This approach to migraine prevention has been a focus of recent pharmacological study.

Key Studies & References

  1. Safety and Efficacy of Atogepant for the Preventive Treatment of Migraines in Adults: A Systematic Review and Meta-Analysis
  2. Anti-CGRP Antibodies Boost Satisfaction and Life Quality in Resistant Migraine (Impact on QoL)

Frequently Asked Questions (FAQ)

Common questions about Ancor Plus (FAQ)


Q: I missed a dose of Ancor Plus, what is the protocol for that?

Official guidance typically states that if a dose is missed, it should be taken as soon as remembered, unless the time is near the next scheduled dose. In that case, the missed dose should be skipped, and the regular schedule continued. Regulatory information stresses the importance of not taking two doses at once to account for a missed dose, as this increases the risk of adverse effects.


Q: Is there a best time of day to take Ancor Plus?

According to the official instructions, Ancor Plus should be taken once daily following a consistent, standardized schedule. The regulatory information does not specify a superior time, such as morning or evening. Consistency in the time of day the medication is taken is emphasized in the regulatory information to help ensure steady levels of the medication in the body.


Q: Can Ancor Plus be taken with or without food?

The official product information clarifies that the absorption of the active ingredients is generally not affected by food. Therefore, the medication may be taken regardless of whether a meal was recently consumed or on an empty stomach.


Q: Can I crush or split my Ancor Plus tablets?

The official product information describes Ancor Plus as an oral tablet. Regulatory guidance generally advises against crushing or splitting tablets unless the medication is specifically designed for it (e.g., if it has a score line). Altering the tablet may affect how the medicine is released and absorbed.


Q: Is Ancor Plus used for more than one condition?

Official documents indicate that Ancor Plus is authorized for the management of hypertension (high blood pressure). In addition, some formulations are authorized for use in the treatment of certain chronic heart conditions, such as stable chronic heart failure or stable chronic angina.


Q: What is the main difference between Ancor Plus and a regular over-the-counter medicine for the same issue?

Ancor Plus is a prescription medication that contains specific, potent components intended to manage chronic, serious medical conditions like hypertension. These components belong to therapeutic classes such as beta-blockers and diuretics. Regular over-the-counter medicines do not typically contain these specific classes or strengths of ingredients.


Q: How long does it usually take to notice the effect of Ancor Plus?

The official label does not provide a specific timeline for when the full therapeutic benefit is generally achieved. However, the regulatory documents note that some initial side effects, such as dizziness or fatigue, are described as being mild and usually resolve within the first one to two weeks of starting treatment.


Q: Is Ancor Plus considered a long-term treatment or short-term?

Ancor Plus is authorized for the long-term management of chronic conditions such as hypertension and stable heart failure. Its intended use, as defined in regulatory documents, is typically for an extended duration, subject to continuous medical review.


Q: What are the most common side effects people report with Ancor Plus?

According to the official product information, the most commonly reported side effects include general complaints such as fatigue, dizziness, and headache. Gastrointestinal issues, including nausea, vomiting, and diarrhea or constipation, are also listed among the frequently described effects.


Q: Does Ancor Plus cause drowsiness or affect my ability to drive?

Official documents indicate that common side effects include dizziness and fatigue. Furthermore, the regulatory characteristics of one active component describe a potential for drowsiness. Regulatory documents note that these potential effects may reduce the ability to drive or operate machinery, particularly when treatment is initiated or the dose is changed.


Q: Is it normal to feel a mild stomach ache when first starting Ancor Plus?

Yes, according to official regulatory documents, gastrointestinal complaints are listed among the commonly reported side effects. This can include stomach ache, nausea, diarrhea, and constipation, especially when first starting the medication.


Q: Can I take Ancor Plus if I also take a common multivitamin?

Official regulatory sources primarily list interactions with other prescription drugs. While multivitamins are not typically listed as contraindications, it is known that the diuretic component of Ancor Plus can influence the body's electrolyte levels, which some supplements may also affect.


Q: Are there any specific foods or drinks that should be avoided while taking Ancor Plus?

Regulatory documents contain information regarding alcohol consumption. Concurrent use of alcohol may enhance certain side effects of Ancor Plus, particularly those related to a drop in blood pressure when changing position (orthostatic hypotension).


Q: What is the risk of Ancor Plus interacting with herbal supplements?

Official regulatory labels detail known drug-drug interactions but do not typically list individual herbal supplements. However, official warnings generally caution against combining Ancor Plus with any product that is known to affect your blood pressure, heart rate, or electrolyte balance, as this may increase the risk of adverse effects.


Q: If I have a mild liver issue, is Ancor Plus still an option?

Official product labeling contains specific warnings and guidance for use in patients with pre-existing liver conditions. Although rare, regulatory documents describe that hepatic enzyme elevations (hepatitis) have been reported as an adverse reaction. The decision to use this medication in the presence of a liver issue should be made by a healthcare professional based on the official guidelines.


Q: Is Ancor Plus safe for use in older adults (seniors)?

Official documents generally suggest no routine dose adjustment is required for elderly patients. However, the label contains a caution regarding the reduced elimination of the diuretic component in individuals with impaired kidney function, which is often more common in older adults.


Q: Is there any information about Ancor Plus use during pregnancy?

Official regulatory documents contain information regarding use during pregnancy. The product is generally categorized to reflect that its use is only considered when the potential benefit to the patient is judged to justify the potential risk to the fetus. Additional medical monitoring is often recommended if the medication is used during pregnancy.


Q: Can Ancor Plus be taken by people under the age of 18?

Official regulatory documents state that there is no established pediatric experience with Ancor Plus. Due to the lack of sufficient studies in younger populations, the medication is typically not recommended or authorized for use in children and adolescents under the age of 18.


Q: What kind of studies or research has been done on Ancor Plus?

The approval of Ancor Plus by regulatory bodies requires extensive clinical studies to demonstrate its safety and effectiveness for its authorized uses. Summaries of these studies, including data on how the drug works and its clinical efficacy, are contained within the official product characteristics.


Q: Why does the packaging for Ancor Plus include a warning about kidney problems?

Official product packaging includes warnings because the diuretic component of Ancor Plus has the potential to cause electrolyte disturbances and fluid imbalances. Additionally, the drug's components are primarily cleared from the body by the kidneys, meaning there is caution for individuals with pre-existing impaired kidney function.


Q: What is meant by the 'active ingredient' in Ancor Plus?

Official product information defines the active ingredients as the specific chemical components responsible for the medicine's intended pharmacological effect. For Ancor Plus, this includes the two separate components that work together—typically a beta-blocker and a diuretic or similar antihypertensive agents.


Q: Does Ancor Plus contain common allergens like gluten or lactose?

Official regulatory documents list all components of the tablet, including both active and inactive ingredients (known as excipients). This complete list is specified in the product information to determine if the medication contains recognized allergens or substances like lactose or gluten.


Q: Is Ancor Plus available generically?

The availability of a generic equivalent is determined by regulatory bodies based on patent exclusivity. Official sources such as the FDA's Orange Book track this status and indicate if a generic, bioequivalent version of Ancor Plus has been approved for market following the expiration of patent protection.


Q: What happens if I stop taking Ancor Plus suddenly?

The official product label includes a warning about the risk of abrupt cessation of therapy. Stopping the medication suddenly can potentially worsen underlying medical conditions, such as angina pectoris, and may increase the risk of serious heart-related events. Official instructions recommend the drug be discontinued gradually.


Q: Can I take Ancor Plus with pain relievers like ibuprofen or aspirin?

Official regulatory documents list known interactions. Warnings often caution against combining Ancor Plus with non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen. This is due to the potential for NSAIDs to reduce the blood pressure-lowering effect of Ancor Plus and potentially affect kidney function.


Q: I see different versions of Ancor Plus online—are they all the same?

The official product labeling documents several approved dosage strengths of Ancor Plus, ranging from the lowest starting dose to the maximum dose. While all versions contain the same active ingredients, they differ in the exact amount of medicine in each tablet.


Q: What is the difference between Ancor Plus and Ancor Plus Forte?

If 'Forte' is an authorized product name, official regulatory documents define it as a higher dosage strength of the same active ingredients found in the standard Ancor Plus. The purpose of these variations is to allow for dosage titration as defined in the official treatment guidelines.


Q: Does Ancor Plus affect blood pressure readings?

Yes, Ancor Plus is indicated for the management of hypertension (high blood pressure). Its primary therapeutic effect, as outlined in official documents, is to lower and help stabilize blood pressure readings.


Q: Is Ancor Plus habit-forming or addictive?

Regulatory bodies classify medications based on their potential for abuse. The active components of Ancor Plus (a beta-blocker and a diuretic) are not classified as controlled substances by regulatory agencies. Therefore, the medication is not generally considered to be habit-forming or addictive.


Q: Are the reported side effects of Ancor Plus rare or common?

Official product documentation classifies adverse events by their frequency to help patients understand prevalence. Side effects are categorized into groups such as 'Very Common,' 'Common' (occurring in at least 1 in 100 people), 'Uncommon,' and 'Rare,' all based on clinical trial data.


Q: What does the FDA classification of Ancor Plus mean?

The FDA classification confirms that Ancor Plus has gone through the official regulatory review process and is an FDA-approved medication. This status indicates that the drug has met the agency’s standards for both safety and effectiveness for its stated medical indications.


Q: Do I need to get blood tests while taking Ancor Plus?

Official regulatory documents warn that the diuretic component can cause electrolyte disturbances and changes in kidney function. The official label suggests specific patient monitoring to address potential changes in electrolytes or kidney function, which may involve periodic blood tests.


Q: What is the maximum duration Ancor Plus is typically prescribed for?

Ancor Plus is indicated for the long-term management of chronic conditions such as hypertension. The regulatory documents confirm its role in chronic care, but the duration of treatment is determined by individual medical assessment.


Q: What kind of pain or discomfort is Ancor Plus specifically intended for?

Ancor Plus is not primarily classified as a general pain reliever. Official documents specify its use is for managing chronic conditions like hypertension (high blood pressure) and, in certain formulations, for managing symptoms related to stable chronic angina or heart failure.


Q: Can I take Ancor Plus if I have diabetes?

Official warnings in the regulatory documents state that the beta-blocker component can potentially mask certain symptoms of low blood sugar (hypoglycemia). The use of Ancor Plus in diabetic patients is described as possible but requires specific caution and careful monitoring, according to official warnings.


Q: Why do some people report feeling tired after taking Ancor Plus?

Fatigue and asthenia (a lack of energy) are specifically listed as Common side effects in the official product characteristics of the active components. This means that feeling tired has been observed and reported by a significant number of people during clinical studies.


Q: Is Ancor Plus a 'first-line' treatment option?

The official product labeling and the treatment guidelines referenced within it typically define the drug's position in therapy for its authorized uses. These guidelines inform whether Ancor Plus is positioned as a first-line agent or a secondary option for conditions like essential hypertension.


Q: What is the typical shelf life of Ancor Plus once the bottle is opened?

Official product documentation contains detailed storage requirements and the defined shelf life of the medicine while sealed. The instructions will specify if the expiry period changes once the sealed bottle or blister pack is first opened, based on formal stability data.


Q: Are there any specific light or temperature requirements for storing Ancor Plus?

Yes, the official product labeling specifies the exact temperature range required for storage. It also details the necessary precautions regarding environmental factors, such as protection from light and moisture, to help maintain the stability and potency of the active ingredients.


Q: What are the major contraindications listed for Ancor Plus?

The official product information lists major contraindications—conditions where the drug should not be used. These typically include severe conditions such as cardiogenic shock, uncontrolled heart failure, certain heart rhythm abnormalities (like second or third-degree AV block), marked sinus bradycardia, and anuria (lack of urine production).


Q: Does alcohol consumption interfere with Ancor Plus?

Official regulatory warnings specifically caution against concurrent alcohol consumption. Alcohol intake may enhance certain side effects, particularly increasing the risk of symptoms like dizziness when standing up (orthostatic hypotension) due to an additive effect on blood pressure lowering.


Q: What are the signs of a serious allergic reaction to Ancor Plus?

Official labeling lists severe adverse events to watch for. Signs of a serious allergic reaction may include swelling of the face, lips, or tongue, the presence of a severe rash or hives, or difficulty breathing. Any indication of these symptoms requires immediate medical attention.


Q: Is Ancor Plus metabolized by the liver?

Official regulatory documents contain a section on the drug's pharmacokinetics (what the body does to the drug). This information details how the active ingredients are absorbed and processed, confirming that one or more of the components are metabolized by the liver before being eliminated.


Q: What happens if I take Ancor Plus on an empty stomach?

The official product information specifies that the drug's absorption is generally not affected by the presence of food. Therefore, taking Ancor Plus on an empty stomach is acceptable according to regulatory information, and its effect is expected to be similar to taking it with a meal.


Q: What information should I know about Ancor Plus and fertility?

Regulatory documents contain data on potential effects related to the reproductive system. For example, some beta-blockers, which are components of Ancor Plus, have been associated with erectile dysfunction as a rare side effect reported in official product characteristics.


Q: Are there different forms of Ancor Plus (tablet, capsule, liquid)?

The official product labeling specifies the authorized pharmaceutical form for this medication. As described in the administration section of the official documents, Ancor Plus is currently administered orally as a tablet.


Q: Does Ancor Plus interact with common sleep aids?

Official regulatory documents list drug interactions. Since Ancor Plus components are known to cause dizziness or drowsiness, the official label cautions that combining it with other agents, such as certain sleep aids that have sedative properties, may increase the risk of these central nervous system effects.


Q: Is Ancor Plus safe for people with heart conditions?

Official warnings state the drug is contraindicated (must not be used) in patients with severe heart conditions such as cardiogenic shock, uncontrolled heart failure, or specific heart rhythm abnormalities (like certain AV blocks). Its use for heart-related issues is strictly defined by the authorized indications.


Q: Is there a patient information leaflet available for Ancor Plus online?

Yes. Regulatory requirements from bodies like the FDA and EMA mandate that the complete Patient Information Leaflet (PIL) or Medication Guide for all approved medicines be made publicly available through official regulatory channels.


Q: What are the known potential drug-disease interactions with Ancor Plus?

Official regulatory documents list specific disease states that either contraindicate its use or require extreme caution. Examples include cardiogenic shock, uncontrolled heart failure, certain chronic lung diseases (like bronchospastic disease), and anuria (lack of urine output).


Q: What is the purpose of the inactive ingredients in Ancor Plus?

Official product documents list all inactive ingredients (excipients). These components are not intended to have a medicinal effect but are included to provide the tablet's structure, ensure its stability over time, and help it dissolve correctly so the active ingredients can be properly absorbed.


How should Ancor Plus be stored and disposed of?

Ancor Plus (Bisoprolol Fumarate and Hydrochlorothiazide) tablets must be stored according to specific regulatory requirements to maintain product stability and protect patient safety.

Storage Conditions

Requirement Specifics from Regulatory Labeling
Temperature Range Store at Controlled Room Temperature (between 15 C and 30 C).
Protection Keep away from heat, moisture, and direct light.
Restrictions Do not freeze and do not store above 30 C.
Packaging Keep in the original, closed container and out of excess moisture.

Disposal and Safety

  • Child Safety: The medicine must be kept out of the sight and reach of children.
  • Disposal: Unused or expired medication must not be flushed down the toilet or thrown in household trash unless specific government instructions advise this. Patients should consult a healthcare professional or pharmacist on how to properly dispose of any unused product in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ancor Plus found in:

A-Z Index: